Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
19 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-09-19
Study Completion Date
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this research study the investigators want to learn more about an alternate, local treatment for skin schwannomas. Specifically, local doxycycline intra-tumoral injection will be performed as a potential treatment for NF2-related skin schwannomas, ultimately reducing the risks and costs associated with standard surgical removal of such skin tumors if successful.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma
NCT02341209
Cutaneous T-cell Lymphoma
Mycosis Fungoides
Sezary Syndrome
TERMINATED
PHASE2
Effects of Doxycycline on Persistent Symptoms Post-neuroborreliosis
NCT01205464
Fatigue
Radicular Pain
Cognitive Dysfunction
+2 more
COMPLETED
NA
Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment
NCT01820910
Marginal Zone Lymphoma of Ocular Adnexal
ACTIVE_NOT_RECRUITING
PHASE2
Doxycycline In Lymphangioleiomyomatosis (LAM)
NCT00989742
Lymphangioleiomyomatosis
Tuberous Sclerosis
COMPLETED
PHASE4
A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India
NCT02929121
Lymphedema
Lymphatic Filariasis
Filariasis
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Design: Interventional Clinical Trial, single-arm, open-label
Estimated Enrollment: Up to 19 participants with NF2-associated cutaneous or subcutaneous schwannomas
Aims: To demonstrate change in peripheral schwannoma size following direct injection into the tumor with doxycycline hyclate.
Nineteen neurofibromatosis type 2-associated peripheral cutaneous or subcutaneous schwannomas between 0.5 cm and 4 cm in greatest diameter will be diagnosed clinically, photographed for documentation of location, and injected with between 0.1 ml to 4 ml of 10mg/ml doxycycline hyclate (Fresenius Kabi, Canton, MA). A maximum of three tumors per patient will be injected. The dose administered will be calculated based on tumor size, not to exceed the estimated volume of the tumor or a maximum of 4 ml. The tumor volume will be estimated by electronic caliper measure of the greatest tumor diameter (D). (V=4/3piR3 where R is the radius (R=D/2) is measured in millimeters and the dose calculated by Vmm3/1000 = injection volume in milliliters). Repeat measures will be made at 6-months and 1-year follow up (+/- 1 month) and documented with electronic calipers and photography. Injection of 1% lidocaine may be given pre-doxycycline to reduce injection pain.
Outcome: The primary outcome will be longitudinal change in tumor maximal diameter measured at 6-months and 1-year compared to baseline defined by a change of 25%. Secondary endpoints include patient reports of paresthesia, pain, skin breakdown or discoloration. Exploratory endpoints will be the change in the sum of maximal diameters.
Estimated Enrollment: Up to 19 participants with NF2-associated cutaneous or subcutaneous schwannomas
Aims: To demonstrate change in peripheral schwannoma size following direct injection into the tumor with doxycycline hyclate.
Nineteen neurofibromatosis type 2-associated peripheral cutaneous or subcutaneous schwannomas between 0.5 cm and 4 cm in greatest diameter will be diagnosed clinically, photographed for documentation of location, and injected with between 0.1 ml to 4 ml of 10mg/ml doxycycline hyclate (Fresenius Kabi, Canton, MA). A maximum of three tumors per patient will be injected. The dose administered will be calculated based on tumor size, not to exceed the estimated volume of the tumor or a maximum of 4 ml. The tumor volume will be estimated by electronic caliper measure of the greatest tumor diameter (D). (V=4/3piR3 where R is the radius (R=D/2) is measured in millimeters and the dose calculated by Vmm3/1000 = injection volume in milliliters). Repeat measures will be made at 6-months and 1-year follow up (+/- 1 month) and documented with electronic calipers and photography. Injection of 1% lidocaine may be given pre-doxycycline to reduce injection pain.
Outcome: The primary outcome will be longitudinal change in tumor maximal diameter measured at 6-months and 1-year compared to baseline defined by a change of 25%. Secondary endpoints include patient reports of paresthesia, pain, skin breakdown or discoloration. Exploratory endpoints will be the change in the sum of maximal diameters.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Neurofibromatosis Type 2
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single Arm Open Label
Open Label
Group Type
EXPERIMENTAL
Doxycycline Injection [Doxy]
Intervention Type
DRUG
Injections between 0.1 ml to 4 ml of 10mg/ml doxycycline hyclate will be administered to a maximum of three tumors per patient. The dose administered will be calculated based on tumor size, not to exceed the estimated volume of the tumor or a maximum of 4 ml. Injection of 1% lidocaine may be given pre-doxycycline to reduce injection pain.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Doxycycline Injection [Doxy]
Injections between 0.1 ml to 4 ml of 10mg/ml doxycycline hyclate will be administered to a maximum of three tumors per patient. The dose administered will be calculated based on tumor size, not to exceed the estimated volume of the tumor or a maximum of 4 ml. Injection of 1% lidocaine may be given pre-doxycycline to reduce injection pain.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Doxycycline Hyclate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients must have a confirmed diagnosis of neurofibromatosis 2 by fulfilling National Institute of Health (NIH) criteria or Manchester criteria, or by detection of a causative mutation in the NF2 gene.
The NIH criteria include presence of:
* Bilateral vestibular schwannomas, OR
* First-degree relative with NF2 and EITHER unilateral eighth nerve mass OR
* Two of the following: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity.
The Manchester criteria include presence of:
* Bilateral vestibular schwannomas, OR First-degree relative with NF2 and EITHER unilateral eighth nerve mass OR - Two of the following: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity OR
* Unilateral vestibular schwannoma AND any two of: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity, OR
* Multiple meningiomas (two or more) AND unilateral vestibular schwannoma OR
* Any two of: schwannoma, glioma, neurofibroma, cataract.
2. Patients must have measurable disease, defined as at least one cutaneous/subcutaneous schwannoma with the following qualities:
* Maximal tumor diameter \> 0.5 cm to \< 4.0 cm that can be accurately measured by electronic calipers
* Up to a maximum of 3 tumors/subject may be injected
* Not located on the face
3. Age ≥ 8 years on day 1 of treatment.
4. Life expectancy of greater than 1 year
5. Lansky/Karnofsky performance status ≥ 60
6. Fully recovered from acute toxic effects of any prior chemotherapy, biological modifiers or radiotherapy
7. Any neurologic deficits must be stable for ≥1 week
8. Patient or parent/legal guardian must be able to provide signed informed consent and assent (as applicable for minors)
The NIH criteria include presence of:
* Bilateral vestibular schwannomas, OR
* First-degree relative with NF2 and EITHER unilateral eighth nerve mass OR
* Two of the following: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity.
The Manchester criteria include presence of:
* Bilateral vestibular schwannomas, OR First-degree relative with NF2 and EITHER unilateral eighth nerve mass OR - Two of the following: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity OR
* Unilateral vestibular schwannoma AND any two of: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity, OR
* Multiple meningiomas (two or more) AND unilateral vestibular schwannoma OR
* Any two of: schwannoma, glioma, neurofibroma, cataract.
2. Patients must have measurable disease, defined as at least one cutaneous/subcutaneous schwannoma with the following qualities:
* Maximal tumor diameter \> 0.5 cm to \< 4.0 cm that can be accurately measured by electronic calipers
* Up to a maximum of 3 tumors/subject may be injected
* Not located on the face
3. Age ≥ 8 years on day 1 of treatment.
4. Life expectancy of greater than 1 year
5. Lansky/Karnofsky performance status ≥ 60
6. Fully recovered from acute toxic effects of any prior chemotherapy, biological modifiers or radiotherapy
7. Any neurologic deficits must be stable for ≥1 week
8. Patient or parent/legal guardian must be able to provide signed informed consent and assent (as applicable for minors)
Exclusion Criteria
1. Allergy to doxycycline or tetracycline
2. Tumors located on the face or major motor nerves
3. Patients currently receiving medical anticancer therapies or who have received medical anticancer therapies within 4 weeks of the start of study drug (including chemotherapy and molecular targeted agents), as these may interfere with the study drug
4. Radiation therapy to a study target tumor within 1 year prior to enrollment, or any radiation therapy within 4 weeks prior to enrollment, as these may interfere with our ability to assess response to study drug
5. Prior treatment with any investigational drug within the preceding 4 weeks, as they may interfere with the study drug
6. Unstable or rapidly progressive disease, including patients who require glucocorticoids for symptomatic control of brain or spinal tumors, as this would represent a high risk for inability to comply with the study requirements
7. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
* symptomatic congestive heart failure of New York heart Association Class III or IV
* unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease
* severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is 90% or less at rest on room air
* active (acute or chronic) or uncontrolled severe infections liver disease, such as cirrhosis or severe hepatic impairment (Child-Pugh class C)
8. Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. Adequate contraception (oral contraceptives, contraceptive implants, vaginal ring, or intrauterine devices (IUDs)) must be used at the time of injection but does not need to be carried out past the 1st month of observation.
9. History of significant noncompliance with follow-up that would jeopardize the study evaluation.
10. Patients unwilling to or unable to comply with the study protocol.
2. Tumors located on the face or major motor nerves
3. Patients currently receiving medical anticancer therapies or who have received medical anticancer therapies within 4 weeks of the start of study drug (including chemotherapy and molecular targeted agents), as these may interfere with the study drug
4. Radiation therapy to a study target tumor within 1 year prior to enrollment, or any radiation therapy within 4 weeks prior to enrollment, as these may interfere with our ability to assess response to study drug
5. Prior treatment with any investigational drug within the preceding 4 weeks, as they may interfere with the study drug
6. Unstable or rapidly progressive disease, including patients who require glucocorticoids for symptomatic control of brain or spinal tumors, as this would represent a high risk for inability to comply with the study requirements
7. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
* symptomatic congestive heart failure of New York heart Association Class III or IV
* unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease
* severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is 90% or less at rest on room air
* active (acute or chronic) or uncontrolled severe infections liver disease, such as cirrhosis or severe hepatic impairment (Child-Pugh class C)
8. Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. Adequate contraception (oral contraceptives, contraceptive implants, vaginal ring, or intrauterine devices (IUDs)) must be used at the time of injection but does not need to be carried out past the 1st month of observation.
9. History of significant noncompliance with follow-up that would jeopardize the study evaluation.
10. Patients unwilling to or unable to comply with the study protocol.
Minimum Eligible Age
8 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts Eye and Ear Infirmary
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
D. Bradley Welling, MD, PhD
Professor Harvard Department of Otolaryngology-Head and Neck Surgery
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
D. Bradley Welling, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts Eye and Ear Infirmary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Massachusetts Eye and Ear
Boston, Massachusetts, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Ren Y, Chari DA, Vasilijic S, Welling DB, Stankovic KM. New developments in neurofibromatosis type 2 and vestibular schwannoma. Neurooncol Adv. 2020 Nov 16;3(1):vdaa153. doi: 10.1093/noajnl/vdaa153. eCollection 2021 Jan-Dec.
Reference Type
BACKGROUND
Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009 Jun 19;4:16. doi: 10.1186/1750-1172-4-16.
Reference Type
BACKGROUND
Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105. doi: 10.1093/neuonc/noab200.
Reference Type
BACKGROUND
Balasubramaniam A, Shannon P, Hodaie M, Laperriere N, Michaels H, Guha A. Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro Oncol. 2007 Oct;9(4):447-53. doi: 10.1215/15228517-2007-027. Epub 2007 Aug 17.
Reference Type
BACKGROUND
Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S. Correction to: An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol. 2020 Apr;139(4):667. doi: 10.1007/s00401-019-02044-6.
Reference Type
BACKGROUND
Petrilli AM, Garcia J, Bott M, Klingeman Plati S, Dinh CT, Bracho OR, Yan D, Zou B, Mittal R, Telischi FF, Liu XZ, Chang LS, Welling DB, Copik AJ, Fernandez-Valle C. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells. Oncotarget. 2017 May 9;8(19):31666-31681. doi: 10.18632/oncotarget.15912.
Reference Type
BACKGROUND
Cosetti MK, Golfinos JG, Roland JT Jr. Quality of Life (QoL) Assessment in Patients with Neurofibromatosis Type 2 (NF2). Otolaryngol Head Neck Surg. 2015 Oct;153(4):599-605. doi: 10.1177/0194599815573002. Epub 2015 Mar 16.
Reference Type
BACKGROUND
Marchi E, Teixeira LR, Vargas FS. Management of malignancy-associated pleural effusion: current and future treatment strategies. Am J Respir Med. 2003;2(3):261-73. doi: 10.1007/BF03256654.
Reference Type
BACKGROUND
Godfrey KJ, Kally P, Dunbar KE, Campbell AA, Callahan AB, Lo C, Freund R, Lisman RD. Doxycycline Injection for Sclerotherapy of Lower Eyelid Festoons and Malar Edema: Preliminary Results. Ophthalmic Plast Reconstr Surg. 2019 Sep/Oct;35(5):474-477. doi: 10.1097/IOP.0000000000001332.
Reference Type
BACKGROUND
Shaye DA, Burks CA, Gadkaree SK, Ncogoza I, Tuyishimire G, Nyabyenda V, Gassore A. Self-compounded Doxycycline Sclerotherapy for the Treatment of Lymphatic Malformations in Low-Resource Settings. World J Surg. 2020 Nov;44(11):3616-3619. doi: 10.1007/s00268-020-05667-z. Epub 2020 Jul 8.
Reference Type
BACKGROUND
Farnoosh S, Don D, Koempel J, Panossian A, Anselmo D, Stanley P. Efficacy of doxycycline and sodium tetradecyl sulfate sclerotherapy in pediatric head and neck lymphatic malformations. Int J Pediatr Otorhinolaryngol. 2015 Jun;79(6):883-887. doi: 10.1016/j.ijporl.2015.03.024. Epub 2015 Apr 6.
Reference Type
BACKGROUND
Tang SJ, Sreenarasimhaiah J, Tang L, Rollins N, Purdy PD. Endoscopic injection sclerotherapy with doxycycline for mediastinal and esophageal lymphangiohemangioma. Gastrointest Endosc. 2007 Dec;66(6):1196-200. doi: 10.1016/j.gie.2007.06.023.
Reference Type
BACKGROUND
Woon JTK, Hoon D, Graydon A, Flint M, Doyle AJ. Aneurysmal bone cyst treated with percutaneous doxycycline: is a single treatment sufficient? Skeletal Radiol. 2019 May;48(5):765-771. doi: 10.1007/s00256-019-03188-y. Epub 2019 Feb 26.
Reference Type
BACKGROUND
Zhu C, Yan X, Yu A, Wang Y. Doxycycline synergizes with doxorubicin to inhibit the proliferation of castration-resistant prostate cancer cells. Acta Biochim Biophys Sin (Shanghai). 2017 Nov 1;49(11):999-1007. doi: 10.1093/abbs/gmx097.
Reference Type
BACKGROUND
Alsaadi M, Tezcan G, Garanina EE, Hamza S, McIntyre A, Rizvanov AA, Khaiboullina SF. Doxycycline Attenuates Cancer Cell Growth by Suppressing NLRP3-Mediated Inflammation. Pharmaceuticals (Basel). 2021 Aug 26;14(9):852. doi: 10.3390/ph14090852.
Reference Type
BACKGROUND
Nicoud IB, Jones CM, Pierce JM, Earl TM, Matrisian LM, Chari RS, Gorden DL. Warm hepatic ischemia-reperfusion promotes growth of colorectal carcinoma micrometastases in mouse liver via matrix metalloproteinase-9 induction. Cancer Res. 2007 Mar 15;67(6):2720-8. doi: 10.1158/0008-5472.CAN-06-3923.
Reference Type
BACKGROUND
Sagar J, Sales K, Taanman JW, Dijk S, Winslet M. Lowering the apoptotic threshold in colorectal cancer cells by targeting mitochondria. Cancer Cell Int. 2010 Sep 6;10:31. doi: 10.1186/1475-2867-10-31.
Reference Type
BACKGROUND
Tan Q, Yan X, Song L, Yi H, Li P, Sun G, Yu D, Li L, Zeng Z, Guo Z. Induction of Mitochondrial Dysfunction and Oxidative Damage by Antibiotic Drug Doxycycline Enhances the Responsiveness of Glioblastoma to Chemotherapy. Med Sci Monit. 2017 Aug 26;23:4117-4125. doi: 10.12659/msm.903245.
Reference Type
BACKGROUND
Reis M, Czupalla CJ, Ziegler N, Devraj K, Zinke J, Seidel S, Heck R, Thom S, Macas J, Bockamp E, Fruttiger M, Taketo MM, Dimmeler S, Plate KH, Liebner S. Endothelial Wnt/beta-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J Exp Med. 2012 Aug 27;209(9):1611-27. doi: 10.1084/jem.20111580. Epub 2012 Aug 20.
Reference Type
BACKGROUND
Zhang L, Xu L, Zhang F, Vlashi E. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017 Apr 18;16(8):737-745. doi: 10.1080/15384101.2016.1241929. Epub 2016 Oct 18.
Reference Type
BACKGROUND
Sharon D, Cathelin S, Mirali S, Di Trani JM, Yanofsky DJ, Keon KA, Rubinstein JL, Schimmer AD, Ketela T, Chan SM. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Sci Transl Med. 2019 Oct 30;11(516):eaax2863. doi: 10.1126/scitranslmed.aax2863.
Reference Type
BACKGROUND
Rok J, Karkoszka M, Rzepka Z, Respondek M, Banach K, Beberok A, Wrzesniok D. Cytotoxic and proapoptotic effect of doxycycline - An in vitro study on the human skin melanoma cells. Toxicol In Vitro. 2020 Jun;65:104790. doi: 10.1016/j.tiv.2020.104790. Epub 2020 Feb 8.
Reference Type
BACKGROUND
Shen LC, Chen YK, Lin LM, Shaw SY. Anti-invasion and anti-tumor growth effect of doxycycline treatment for human oral squamous-cell carcinoma--in vitro and in vivo studies. Oral Oncol. 2010 Mar;46(3):178-84. doi: 10.1016/j.oraloncology.2009.11.013. Epub 2009 Dec 29.
Reference Type
BACKGROUND
Hadjimichael AC, Foukas AF, Savvidou OD, Mavrogenis AF, Psyrri AK, Papagelopoulos PJ. The anti-neoplastic effect of doxycycline in osteosarcoma as a metalloproteinase (MMP) inhibitor: a systematic review. Clin Sarcoma Res. 2020 Apr 30;10:7. doi: 10.1186/s13569-020-00128-6. eCollection 2020.
Reference Type
BACKGROUND
Lee MJ, Hung SH, Huang MC, Tsai T, Chen CT. Doxycycline potentiates antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy in malignant peripheral nerve sheath tumor cells. PLoS One. 2017 May 30;12(5):e0178493. doi: 10.1371/journal.pone.0178493. eCollection 2017.
Reference Type
BACKGROUND
Ren Y, Hyakusoku H, Sagers JE, Landegger LD, Welling DB, Stankovic KM. MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas. Front Cell Neurosci. 2020 Jul 28;14:191. doi: 10.3389/fncel.2020.00191. eCollection 2020.
Reference Type
BACKGROUND
Sagers JE, Sahin MI, Moon I, Ahmed SG, Stemmer-Rachamimov A, Brenner GJ, Stankovic KM. NLRP3 inflammasome activation in human vestibular schwannoma: Implications for tumor-induced hearing loss. Hear Res. 2019 Sep 15;381:107770. doi: 10.1016/j.heares.2019.07.007. Epub 2019 Jul 17.
Reference Type
BACKGROUND
Thalheimer RD, Merker VL, Ly KI, Champlain A, Sawaya J, Askenazi NL, Herr HP, Da JLW, Jordan JT, Muzikansky A, Pearce EM, Sakamoto FH, Blakeley JO, Anderson RR, Plotkin SR; REiNS International Collaboration. Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials. Neurology. 2021 Aug 17;97(7 Suppl 1):S32-S41. doi: 10.1212/WNL.0000000000012428. Epub 2021 Jul 6.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022P000534
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Injection Sclerotherapy With Bleomycin VS Doxycycline in Patients With Lymphatic Malformations
NCT07320001
NOT_YET_RECRUITING
PHASE2
Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis
NCT02553473
COMPLETED
PHASE3
Doxycycline for Hereditary Hemorrhagic Telangiectasia
NCT03397004
COMPLETED
PHASE2
A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali
NCT02927496
COMPLETED
PHASE3
A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka
NCT02929134
COMPLETED
PHASE3
Doxecitine and Doxribtimine-Expanded Access
NCT06590493
AVAILABLE
A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo
NCT01803035
COMPLETED
PHASE2
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease
NCT00001101
COMPLETED
PHASE3
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease
NCT00000938
COMPLETED
PHASE3
Randomized Controlled Trial of Doxycycline to Prevent Acquisition of Mycoplasma Pneumoniae in an Outbreak Setting
NCT00207584
COMPLETED
NA
Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial
NCT02207556
COMPLETED
PHASE2
Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis
NCT00138801
COMPLETED
PHASE3
Safety and Effect of Doxycycline in Patients With Amyloidosis
NCT01677286
COMPLETED
PHASE2
Doxycycline and Ceftriaxone in Suspected Early Lyme Neuroborreliosis
NCT00942006
UNKNOWN
NA
Ceftriaxone for Post-Treatment Lyme Disease
NCT06785402
RECRUITING
PHASE1/PHASE2
Xenodiagnosis After Antibiotic Treatment for Lyme Disease
NCT02446626
COMPLETED
NA
Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis
NCT02016365
COMPLETED
PHASE2
Laboratory Characteristics in Chronic Atrophic Acrodermatitis
NCT02147262
UNKNOWN
NA
Doxycycline Boosted Therapy in Lyme Borreliosis: DoBo Study.
NCT07230028
NOT_YET_RECRUITING
PHASE4
Study of Lyme Neuroborreliosis
NCT01635530
COMPLETED
PHASE4
Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease
NCT01917721
ACTIVE_NOT_RECRUITING
PHASE2
Does Preoperative Administration of Oral Doxycycline Decrease the Colonization Rate of Propionibacterium Acnes in the Dermis of the Shoulder?
NCT02688738
UNKNOWN
NA
Clinical Trial of Doxycycline VS BPG for Early Syphilis (SY-DOXY)
NCT04838717
COMPLETED
PHASE3
Doxycycline in Therapy of Erythema Migrans
NCT01475708
COMPLETED
Safety, Skin and Plasma Concentration of Azithromycin Dermal Formulation
NCT01243008
COMPLETED
PHASE1/PHASE2